Reveal is transforming medical insight with the first gadolinium-free general purpose MRI contrast agent RVP-001 (Phase 2 clinical studies) and fibrogenesis-targeted imaging agents (pre-clinical). Our imaging agents are based on technology invented at the Caravan Lab at Harvard Medical School and have broad potential applicability to many disease indications from oncology through CNS to fibrotic diseases for diagnosis, patient management, and study read out.